Title: Treatment for Graves’ Disease and its Recurrence
Authors: Dr S. Zahir Hussain, Dr M.P. Kumaran
DOI: https://dx.doi.org/10.18535/jmscr/v5i7.100
Abstract
INTRODUCTION
The most common cause of hyperthyroidism worldwide is Graves’ disease (GD). Therapeutic options for GD include anti thyroid drugs (ATD), radioactive iodine, and thyroidectomy. ATD treatment is generally well accepted by patients because it normalize thyroid function in a short time, rarely causing hypothyroidism, and ameliorating immune disorder while avoiding radiation exposure and invasive procedures. However, the relapse rate is a major concern for ATD treatment, the rate of relapse depends on the factors like clinical characteristics, treatment strategies, and genetic and environmental factors. Of these influencing factors, some are modifiable but some are non modifiable. The recurrence risk can be reduced by adjusting the modifiable factors as much as possible. The titration regimen for 12–18 months is the optimal strategy of ATD. Levothyroxine administration after successful ATD treatment was not recommended. The addition of immunosuppressive drugs might be helpful to decrease the recurrence rate of GD patients after ATD withdrawal, whereas further studies are needed to address the safety and efficacy
References
1. S. De Leo, S. Y. Lee, and L. E. Braverman, “Hyperthyroidism,” Lancet, vol. 388, no. 10047, pp. 906–918, 2016.
2. V. Sundaresh, J. P. Brito, Z. Wang et al., “Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis,” The Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 9, pp. 3671–3677, 2013.
3. C. Ma, J. Xie, H. Wang, J. Li, and S. Chen, “Radioiodine therapy versus antithyroid medications for Graves’ dis-ease,” Cochrane Database of Systematic Reviews, vol. 2, article CD010094, 2016.
4. D. S. Cooper, “Antithyroid drugs,” The New England Journal of Medicine, vol. 352, no. 9, pp. 905–917, 2005.
5. X. G. Vos, E. Endert, A. H. Zwinderman, J. G. Tijssen, and W. M. Wiersinga, “Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism,” The Journal of Clinical Endocrinology and Metabolism, vol. 101, no. 4, pp. 1381–1389, 2016.
6. K. W. Kim, Y. J. Park, T. Y. Kim, D. J. Park, K. S. Park, and B. Y. Cho, “Susceptible alleles of the CD40 and CTLA-4 genes are not associated with the relapse after antithyroid withdrawal in Graves’ disease,” Thyroid, vol. 17, no. 12, pp. 1229–1234, 2007.
7. H. Allannic, R. Fauchet, J. Orgiazzi et al., “Antithyroid drugs and Graves’ disease: a prospective randomized evaluation of the efficacy of treatment duration,” Journal of Clinical Endo-crinology and Metabolism, vol. 70, no. 3, pp. 675–679, 1990.
8. L. Liu, H. Lu, Y. Liu, C. Liu, and C. Xun, “Predicting relapse of Graves’ disease following treatment with antithyroid drugs,” Experimental and Therapeutic Medicine, vol. 11, no. 4, 1443–1458, 2016.
9. D. S. Ross, H. B. Burch, D. S. Cooper et al., “2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis,” Thyroid, vol. 26, no. 10, pp. 1343–1421, 2016.
10. P. Abraham, A. Avenell, S. C. McGeoch, L. F. Clark, and J. S. Bevan, “Antithyroid drug regimen for treating Graves’ hyperthyroidism,” Cochrane Database of Systematic Reviews, vol. 20, no. 1, p. CD003420, 2010.
11. P. A. Dahlberg, F. A. Karlsson, B. Lindstrom, and L. Wide, “Studies of thyroid hormone and carbimazole levels in patients with Graves’ disease on a standardized anti-thyroid drug regimen,” Clinical Endocrinology, vol. 14, no. 6,555–562, 1981.
12. C. Liu, Y. Duan, and X. Wu, “Prospective study on the relationship between treatment duration of antithyroid drug and remission rate of Graves’ disease,” Zhonghua Yi Xue Za Zhi, vol. 80, no. 11, pp. 835–837, 2000.
13. E. Mazza, M. Carlini, D. Flecchia et al., “Long-term follow-up of patients with hyperthyroidism due to Graves’ disease treated with carbimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treat-ment with low carbimazole doses: a retrospective study,” Journal of Endocrinological Investigation, vol. 31, no. 10, pp 866–872, 2008.
14. D. Glinoer, P. De Nayer, and M. Bex, “Effects of L-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves’ hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study,” European Journal of Endocrinology, vol. 144, no. 5,pp 475–483, 2001.
15. A. Antonelli, S. M. Ferrari, A. Corrado, A. Di Domenicantonio, and P. Fallahi, “Autoimmune thyroid disorders,” Autoimmu-nity Reviews, vol. 14, no. 2, pp. 174–180, 2015.
16. G. Obiols Alfonso, J. Mesa Manteca, R. Simo Canonge, L. García Pascual, C. García Alonso, and J. M. Tresánchez Trías, “Effect of carbimazole and dexamethasone on the TSH bond (TBII) inhibiting immunoglobulins in Graves-Basedow disease,” Revista Clínica Española, vol. 183, no. 8, pp 401–404, 1988.
17. L. Chen, H. Q. Wang, Y. Y. Gao et al., “Comparison of methi-mazole/hydrocort-isone ointment with oral carbimazole in patients with Graves disease: a prospe-ctive, randomized, open-label, parallel-group, 18-month study,” Current Thera-peutic Research, Clinical and Experim-ental, vol. 69, no. 4,qq 305–317, 2008.
18. T. Struja, L. Guebelin, A. Kutz, H. Fehlberg, B. Mueller, and P. Schuetz, “Does immunosuppressive therapy improve outcomes in Graves’ disease? A systematic review and meta-analysis,” Thyroid, vol. 26, no. 5, pp. 634–640, 2016.
19. A. Carle, I. B. Pedersen, N. Knudsen et al., “Epidemiology of subtypes of hyperthyroidism in Denmark: a population-based study,” European Journal of Endocrinology, vol. 164, no. 5, pp. 801–809, 2011.
20. E. Mohlin, H. Filipsson Nystrom, and M. Eliasson, “Long-term prognosis after medical treatment of Graves’ disease in a northern Swedish population 2000-2010,” European Journal of Endocrinology, vol. 170, no. 3, pp. 419–427, 2014.
21. B. Quadbeck, U. Roggenbuck, O. E. Janssen et al., “Impact of smoking on the course of Graves’ disease after withdrawal of antithyroid drugs,” Experimental and Clinical Endocrinology and Diabetes, vol. 114, no. 8, pp. 406–411, 2006.
22. Z. Gerenova and Y. Vulkov, “Clinical significance of serum T3/T4 ratio in the course of antithyroid drug therapy in Graves’ disease patients,” Bulletin Médical, vol. 8, no. 2, pp. 11–13, 2000.
23. S. Hwang, Y. Cho, D. Y. Shin, M. K. Song, and E. J. Lee, “High cut-off value of a chimeric TSH receptor (Mc4)-based bioas-say may improve prediction of relapse in Graves’ disease for 12 months,” Endocrine, vol. 48, no. 1, pp. 89–95, 2015.
24. G. Barbesino and Y. Tomer, “Clinical review: clinical utility of TSH receptor antibodies,” The Journal of Clinical Endocrinol-ogy and Metabolism, vol. 98, no. 6, pp. 2247–2255, 2013.
25. C. Giuliani, D. Cerrone, N. Harii et al., “A TSHR-LH/CGR chimera that measures functional thyroid-stimulating auto-antibodies (TSAb) can predict remission or recurrence in Graves’ patients undergoing antithyroid drug (ATD) treat-ment,” The Journal of Clinical Endocrinology and Metabo-lism, vol. 97, no. 7, pp. E1080–E1087, 2012.
26. O. Eber and W. Langsteger, “Clinical aspects of autoimmune thyroid diseases,” Acta Medica Austriaca, vol. 21, no. 1, 1–7, 1994.
27. T. Sato, I. Takata, T. Taketani, K. Saida, and H. Nakajima, “Concurrence of Graves’ disease and Hashimoto’s thy-roiditis,” Archives of Disease in Childhood, vol. 52, no. 12, 951–955, 1977.
28. P. Laurberg, B. Nygaard, S. Andersen et al., “Association between TSH-receptor autoimmunity, hyperthyroidism, goi-tre, and orbitopathy in 208 patients included in the remission induction and sustenance in Graves’ disease study,” Journal of Thyroid Research, vol. 2014, Article ID 165487, 6 pages, 2014.
29. A. K. Eckstein, H. Lax, C. Losch et al., “Patients with severe Graves’ ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely in remission,” Clinical Endocrinology, vol pp. 607–612, 2007
30. R. Vita, D. Lapa, F. Trimarchi, and S. Benvenga, “Certain HLA alleles are associated with Graves’ disease (GD) in patients in whom hyperthyroidism is preceded by stressful events (SE),” in Thyroid, R. Vita, D. Lapa, F. Trimarchi and S. Benvenga, Eds., vol. 25, p. A205, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy, 2015.
31. F. Azizi, “Environmental iodine intake affects the response to carbimazole in patients with diffuse toxic goiter,” The Journal of Clinical Endocrinology and Metabolism, vol. 61, no. 2, pp. 374–377, 1985.
32. B. L. Solomon, J. E. Evaul, K. D. Burman, and L. Wartofsky, “Remission rates with antithyroid drug therapy: continuing influence of iodine intake?” Annals of Internal Medicine, vol. 107, no. 4, pp. 510–512, 1987.
33. F. Baeke, T. Takiishi, H. Korf, C. Gysemans, and C. Mathieu, “Vitamin D: modulator of the immune system,” Current Opinion in Pharmacology, vol. 10, no. 4, pp. 482–496, 2010.
34. A. P. Weetman, “Graves’ disease,” The New England Journal of Medicine, vol. 343, no. 17, pp. 1236–1248, 2000.
35. X. Liu, W. Qiang, L. Liu et al., “A second course of antithyroid drug therapy for recurrent Graves’ disease: an experience in endocrine practice,” European Journal of Endocrinology, vol. 172, no. 3, pp. 321–326, 2015.
36. D. Villagelin, J. H. Romaldini, R. B. Santos, A. B. Milkos, and L. S. Ward, “Outcomes in relapsed Graves’ disease patients following radioiodine or prolonged low dose of carbimazole treatment,” Thyroid, vol. 25, no. 12, pp. 1282–1290, 2015.
